소디움채널 유전자변이와 카바마제핀의 항경련효과
Polymorphisms in the Voltage-gated Sodium Channel Genes and Antiepileptic Efficacy of Carbamazepin
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Voltage-gated sodium channels are responsible for the initial-depolarization component of action potentials in brain neurons, and hence they are the target for widely used antiepileptic drugs such as carbamazepine (CBZ). With the working hypothesis that genetic defect in voltage-gated sodium channels can alter the response to CBZ, this study was performed to elucidate the relationship between single-nucleotide polymorphisms (SNPs) of the SCN1A, SCN1B, and SCN2A genes and CBZ resistance in Korean epileptics. Methods: Candidate SNPs of SCN1A, SCN1B, and SCN2A were developed using the pooled DNA from healthy controls (n=200), of which representative SNPs of each of SCN1A, SCN1B, and SCN2A were determined based on theoretical functional values. Each representative SNP was genotyped for a CBZ-resistant group (CRE, n=168) and a CBZ- responsive group (CSE, n=154), and the frequencies of alleles and genotypes of each SNP were compared between the two groups. Results: Eighteen SNPs were developed in SCN1A, SCN1B, and SCN2A. SCN1A-PM in exon 16 of SCN1A, SCN1B-PM in exon 3 of a splicing variant of SCN1B, and SCN2A-PM in the 7th intronic sequence of SCN2A were selected as the representative SNPs for these genes. The distributions of alleles and genotypes of each representative SNP did not differ between the CRE and CSE groups. Conclusions: In Korean epileptics, there appears to be no significant relationship between representative SNPs of SCN1A, SCN1B, and SCN2A and CBZ resistance.
Abstract
Background: Voltage-gated sodium channels are responsible for the initial-depolarization component of action potentials in brain neurons, and hence they are the target for widely used antiepileptic drugs such as carbamazepine (CBZ). With the working hypothesis that genetic defect in voltage-gated sodium channels can alter the response to CBZ, this study was performed to elucidate the relationship between single-nucleotide polymorphisms (SNPs) of the SCN1A, SCN1B, and SCN2A genes and CBZ resistance in Korean epileptics. Methods: Candidate SNPs of SCN1A, SCN1B, and SCN2A were developed using the pooled DNA from healthy controls (n=200), of which representative SNPs of each of SCN1A, SCN1B, and SCN2A were determined based on theoretical functional values. Each representative SNP was genotyped for a CBZ-resistant group (CRE, n=168) and a CBZ- responsive group (CSE, n=154), and the frequencies of alleles and genotypes of each SNP were compared between the two groups. Results: Eighteen SNPs were developed in SCN1A, SCN1B, and SCN2A. SCN1A-PM in exon 16 of SCN1A, SCN1B-PM in exon 3 of a splicing variant of SCN1B, and SCN2A-PM in the 7th intronic sequence of SCN2A were selected as the representative SNPs for these genes. The distributions of alleles and genotypes of each representative SNP did not differ between the CRE and CSE groups. Conclusions: In Korean epileptics, there appears to be no significant relationship between representative SNPs of SCN1A, SCN1B, and SCN2A and CBZ resistance.
참고문헌 (21)
- Kwan P, "Early identification of refractory epilepsy", N Engl J Med, 342, pp.314~319 (2000)
- Evans WE, "Pharmacogenomics--drug disposition, drug targets, and side effects", N Engl J Med, 348, pp.538~549 (2003)
- Mann MW, "Various pharmacogenetic aspects of antiepileptic drug therapy: a review", CNS Drugs, 21, pp.143~164 (2007)
- Depondt C, "The potential of pharmacogenetics in the treatment of epilepsy", Eur J Paediatr Neurol, 10, pp.57~65 (2006)
- Siddiqui A, "Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1", N Eng1 J Med, 348, pp.1442~1448 (2003)
- Kim YO, "Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics", Seizure, 15, pp.67~72 (2006)
- Remy S, "Molecular and cellular mechanisms of pharmacoresistance in epilepsy", Brain, 129, pp.18~35 (2006)
- Ferraro TN, "The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview", Epilepsy Behav, 7, pp.18~36 (2005)
- Rogawski MA, "The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions", Nat Med, 10, pp.685~692 (2004)
- Remy S, "A novel mechanism underlying drug resistance in chronic epilepsy", Ann Neurol, 53, pp.469~479 (2003)
- Collins FS, "Variations on a theme: cataloging human DNA sequence variation", Science, 278, pp.1580~1581 (1997)
- Schafer AJ, "DNA variation and the future of human genetics", Nat Biotechnol, 16, pp.33~39 (1998)
- Abe T, "Association between SCN1A polymorphism and carbamazepine-resistant epilepsy", Br J Clin Pharmacol, 66, pp.304~307 (2008)
- Kwan P, "Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression", Pharmacogenet Genomics, 18, pp.989~998 (2008)
- Kwok PY, "Comparative analysis of human DNA variations by fluorescence-based sequencing of PCR products", Genomics, 23, pp.138~144 (1994)
- Meldrum BS, "Molecular targets for antiepileptic drug development", Neurotherapeutics, 4, pp.18~61 (2007)
- Qu Y, "Functional roles of the extracellular segments of the sodium channel alpha subunit in voltage-dependent gating and modulation by beta1 subunits", J Biol Chem, 274, pp.32647~32654 (1999)
- McClatchey AI, "The cloning and expression of a sodium channel beta-1-subunit cDNA from human brain", Hum Molec Genet, 2, pp.745~749 (1993)
- Yamakawa K, "Epilepsy and sodium channel gene mutations: gain or loss of function?", Neuroreport, 16, pp.1~3 (2005)
- Riley JH, "The use of single nucleotide polymorphisms in the isolation of common disease genes", Pharmacogenomics, 1, pp.39~47
- Kim YO, "Frequencies of single nucleotide polymorphisms of the multidrug resistance 1 gene in a Korean population", Korean J Genetics, 28, pp.27~34 (2006)